Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
929046-33-3
Molecular formula
C33H35F7N4O3
Molecular weight
668.6 g/mol
Drug class
Neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonistnon-hormonal therapy for menopausal vasomotor symptoms
Mechanism of action
Antagonises NK1 and NK3 receptors in thermoregulatory pathways, modulating neurokinin-mediated signalling involved in menopausal vasomotor symptoms. It is not an oestrogen replacement therapy.
Indications / reported uses
Treatment of moderate-to-severe vasomotor symptoms (hot flushes and night sweats) due to menopause under the US FDA LYNKUET indication approved in 2025
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Elinzanetant PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Elinzanetant Permitted Daily Exposure (PDE) report (the Elinzanetant PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Elinzanetant Occupational Exposure Limit (OEL) report (the Elinzanetant OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.